EAH Eco Animal Health Group Plc

TIDMEAH

Eco Animal Health Group PLC

28 September 2023

28 September 2023

ECO Animal Health Group plc

("ECO", the "Company" or the "ECO Group")

(AIM: EAH)

ESG Rating

ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that it has achieved an A-rating for its ESG activities from Integrum ESG, who provide independent ESG ratings to a large number of companies.

An 'A' rating is the highest score possible and higher than approximately 300 other companies ranked in the same sub-sector. The rating reflects the ECO ESG strategy and activities and metrics, which are focused especially on environmental and social, particularly ethnic and gender diversity, aspects.

David Hallas, CEO commented: "ECO is committed to embedding sustainability into the high standards set for its business dealings. We recognise the value of incorporating the principles of Environment, Social and Governance (ESG) into everything we do and aspire to contribute to six of the UN SDGs which are aligned with our current and future business and intentions."

For further information please contact:

 
 ECO Animal Health Group plc 
  David Hallas (CEO) 
  Christopher Wilks (CFO)                       020 8447 8899 
 
   IFC Advisory 
   Graham Herring 
   Zach Cohen                                     020 3934 6630 
 
   Singer Capital Markets (Nominated Adviser 
   & Joint Broker) 
   Phil Davies 
   Sam Butcher                                    020 7496 3000 
 
   Investec (Joint Broker) 
   Gary Clarence 
   Lydia Zychowska 
   Carlo Spingardi                                020 7597 5970 
 
 
 Equity Development 
  Hannah Crowe 
  Matt Evans           020 7065 2692 
 

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRALRMJTMTTTBRJ

(END) Dow Jones Newswires

September 28, 2023 02:00 ET (06:00 GMT)

Eco Animal Health (LSE:EAH)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Eco Animal Health (LSE:EAH)
Gráfica de Acción Histórica
De May 2023 a May 2024